Novartis (NOVN.VX: Quote, Profile, Research) is still considering a white knight bid for Franco-German drugmaker Aventis (AVEP.PA: Quote, Profile, Research) but the talks are not yet at a serious stage, a source familiar with the situation told Reuters on Thursday.
